A randomized, multi-center, double-blind, double-dummy, parallel-group, 8 week pilot study, to investigate the effect of QMF Twisthaler (250/400 microg q.d. evening) compared to fluticasone propionate/salmeterol (250/50 microg b.i.d.) FSC in patients with Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A randomized, multi-center, double-blind, double-dummy, parallel-group, 8 week pilot study, to investigate the effect of QMF Twisthaler (250/400 microg q.d. evening) compared to fluticasone propionate/salmeterol (250/50 microg b.i.d.) FSC in patients with Chronic Obstructive Pulmonary Disease (COPD).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2012

At a glance

  • Drugs Indacaterol/mometasone; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2011 This trial is recruiting in Spain and Slovakia, and has completed in Czech Republic.
    • 05 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top